The spin-off Ziylo, from the University of Bristol, has been sold to pharmaceutical giant Novo Nordisk who now hopes to transform the way diabetics are treated . Before the takeover, Ziylo worked on an innovative technology platform that could potentially react and adapt to glucose levels in the blood, reducing or eliminating some of the greatest risks diabetics face (hypoglycaemia) and offering an overall improved quality of life .
The acquisition by Novo Nordisk, one of the leaders in diabetes, offers the potential to bring innovative treatment to diabetes patients . It is estimated that diabetes affects over 382 million people around the world and all of those with Type 1, and some with Type 2, must take insulin to regulate their blood sugar levels .
The deal, potentially worth around €700 m, is one of the biggest in the University’s history. The company was co-founded between University Professor Anthony Davis and a PhD student (Dr Harry Destecroix), and a businessman (Tom Smart) in 2014 .The current product is based on Professor Davis’s research involving synthetic sugar receptors that has been building for over 20 years. The company founders will remain with the company during the continued research and development of the resulting treatment.